BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260223
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T010901
CREATED:20251021T104830Z
LAST-MODIFIED:20251021T104830Z
UID:42225-1771804800-1772150399@www.pharmajournalist.com
SUMMARY:16th World ADC London
DESCRIPTION:The Longest Standing & Pre-Eminent European ADC Forum\n16th World ADC London | 800+ Industry Attendees | 240+ Companies | 110+ Global Speakers \nWith traditional ADCs now fulfilling their potential to reshape oncology care\, the bioconjugate community is doubling down on differentiation to ensure the next generation delivers meaningful patient impact. \nReturning as the longest-standing and definitive ADC forum in Europe\, 16th World ADC London 2026 is the must-attend event for anyone working in or looking to learn about bioconjugates. Leverage cutting-edge R&D\, strategic insights\, and unparalleled networking to advance ADC innovation and maximise therapeutic potential. \nAgenda Highlights:\nThe 2026 programme features 5 end-to-end content streams covering discovery\, preclinical translation\, clinical lessons\, process & analytical development\, and manufacturing & supply chain. Sessions are infused with trailblazing approaches to overcome patient resistance and accelerate ADCs into earlier-line oncology treatments. Topics include: \n\nNovel cytotoxic and non-cytotoxic payloads\nDual payload ADCs\nBispecific and biparatopic ADCs\nNon-antibody and fragment conjugates\n\nGlobal Speaker Faculty:\nHear from 110+ experts across Europe\, North America\, and Asia sharing actionable insights to advance your pipeline\, including: \n\nElaine Hurt\, Executive Director & Head\, Tumour Targeted Delivery Bioscience\, Oncology R&D\, AstraZeneca\nGuillaume Bergthold\, Executive Director\, Clinical Development\, Daiichi Sankyo\nAlan Russell\, VP Research & Head\, R&D Technology & Innovation\, Amgen\nAndras Strassz\, Chief Medical Officer\, Heidelberg Pharma\nMarija Vrljic\, VP\, Antibody Technologies\, ALX Oncology (New Company)\nJonathan Davis\, Director\, ADC Discovery\, Helix Biopharma (New Company)\nZhenwei Miao\, Founder & Chairman\, Adcoris Biopharma (New Company)\n\nWho Will Attend:\nJoin 800+ senior ADC decision-makers from biopharma\, clinical research\, service providers\, investors\, and regulators\, uniting to shape the future of ADC development. \nExplore the full agenda for a complete breakdown of all sessions\, speakers\, and networking opportunities.
URL:http://www.pharmajournalist.com/event/16th-world-adc-london/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T010901
CREATED:20251121T123049Z
LAST-MODIFIED:20251121T123049Z
UID:42464-1771891200-1772150399@www.pharmajournalist.com
SUMMARY:Measuring Impact in Medical Affairs Summit
DESCRIPTION:The Measuring Impact in Medical Affairs Summit is uniting Medical Affairs leaders from across pharma and biotech to define\, benchmark\, and standardize meaningful KPIs that capture the true value of Medical Affairs activities. \nAs Medical Affairs cements its role as the strategic bridge between R&D and commercialization\, the pressure to quantify and communicate impact has never been greater. In an era of tighter budgets\, digital transformation\, and AI-driven analytics\, teams must move beyond activity tracking to demonstrate measurable outcomes that drive scientific\, stakeholder\, and commercial success. \nThis year\, join 50+ experts from Boehringer Ingelheim\, Abbvie\, Alexion\, Travere\, Regeneron\, and more to explore how leading teams are designing metrics that reflect quality over quantity\, leveraging AI to enhance insight generation\, and co-creating the next generation of KPIs defining Medical Affairs excellence. Don’t miss the only meeting dedicated to transforming Medical Affairs from an activity-based to an impact-driven function. \nFind out more: https://ter.li/ymwe2l
URL:http://www.pharmajournalist.com/event/measuring-impact-in-medical-affairs-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T010901
CREATED:20251204T130129Z
LAST-MODIFIED:20251204T130911Z
UID:42543-1771891200-1772150399@www.pharmajournalist.com
SUMMARY:3rd IMPACCT Real World Evidence Summit Europe
DESCRIPTION:As regulators and payers increasingly elevate the importance of RWE in submission and reimbursement requirements\, the upcoming EHDS regulation marks a landmark move towards data sharing\, and increasingly robust AI transforms big data analysis\, it has never been more critical to harness RWE to uncover unmet needs\, demonstrate treatment value beyond the clinical trial setting\, and influence decision-making across regulators\, payers\, providers\, and patients. \nThe 3rd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE\, Evidence Generation\, and Medical Affairs to consolidate\, innovate and apply RWE across the drug development lifecycle\, from external control arms to reimbursement. \nWith a tight focus on leveraging AI for big data analysis\, accessing standardised and high-quality datasets\, and creating a robust integrated evidence strategy\, join 60+ industry pioneers from AstraZeneca\, Pfizer\, Novartis\, Boehringer Ingelheim and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice. \nTo learn more and download the agenda\, please click here.
URL:http://www.pharmajournalist.com/event/3rd-impacct-real-world-evidence-summit-europe/
LOCATION:Radisson Blu Hotel\, Rusland 17\, Amsterdam\, 1012 CK\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T010901
CREATED:20251204T131433Z
LAST-MODIFIED:20251204T131433Z
UID:42559-1771891200-1772150399@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences Europe 2026
DESCRIPTION:Now in its 8th year\, LEAP HR: Life Sciences Europe is where the industry’s most ambitious HR leaders come together to find new solutions to their most pressing people challenges that they can immediately deploy to demonstrate meaningful business impact. Uncover the boldest strategies for driving talent agility\, embedding AI and analytics\, and building future-ready workforces – proven to cut costs\, boost engagement\, and accelerate growth. \nThis is the only forum dedicated to the unique and specific HR\, L&D\, and TA opportunities and challenges faced by life science organisations of all sizes across Europe. Join us next February to collaborate with like-minded HR leaders and uncover how to attract\, develop\, and retain top talent in a rapidly changing landscape. \nOver three jam-packed days\, gain actionable takeaways with proven ROI through case studies\, structured networking\, dedicated panels\, roundtable discussions\, and speed learning sessions. Topics range from employment engagement in uncertain marketers to AI-driven HR innovation\, creative compensation design\, and more. \nYou’ll connect with peers who are reimagining HR’s role as driver of strategic value and organizational impact\, sharing real-world case studies\, practical solutions\, with the ROI behind every leap. \nTo learn more and download the agenda\, please click here.
URL:http://www.pharmajournalist.com/event/leap-hr-life-sciences-europe-2026/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260226
DTEND;VALUE=DATE:20260228
DTSTAMP:20260515T010901
CREATED:20251009T103636Z
LAST-MODIFIED:20251009T103636Z
UID:42156-1772064000-1772236799@www.pharmajournalist.com
SUMMARY:Targeted Therapies Partnering & Licensing Summit Asia
DESCRIPTION:Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster\, & Biotech Access to International Partnerships & Capital \nWith fast\, cost-effective clinical infrastructure\, generous government incentives\, and simplified regulatory pathways\, Asia’s biotech ecosystem has emerged as a global launchpad for innovation. Western pharma and biotech companies are increasingly turning to de-risked assets from Asia to supercharge their clinical pipelines and gain a competitive edge. \nFor NewCo\, private and public biotech or small pharma\, this accessible forum offers: \n\nHigh seniority and quality of attendees across pharma and other biotech\nTargeted focus\, purpose-built format\, and One-on-One Partnering™ portal allowing you to make meaningful connections easier and more efficient\nInformative presentations and discussions nuanced to considerations for deal-making across targeted therapies\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/targeted-therapies-partnering-licensing-summit-asia/
LOCATION:The Westin Tokyo\, 1-4-1 Mita Meguro-ku\, Tokyo\, Tokyo 153-8580\, Japan
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
END:VCALENDAR